Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response
The 'Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response' is a closed Horizon Europe grant under the Innovative Health Initiative Joint Undertaking (IHI JU). This program was designed to advance precision medicine by supporting the rigorous clinical validation of biomarkers and the innovative technologies required for their accessibility and use in clinical settings.
Who is Funded
This section provides an overview of the eligible participants, the geographical scope of the program, and its core objectives. The program targeted a broad range of entities and aimed to address unmet public health needs through advanced biomarker research and technology.
What is Funded
This section details the types of projects and thematic areas supported by the program, focusing on innovations in diagnostic and treatment technologies based on biomarkers. It highlights the expected maturity level of funded projects and outlines cost considerations.
Type and Scope of Funding
This section outlines the financial details of the funding, including the type of instrument used and the expected funding amounts for individual projects. It highlights the program's financial support structure.
Conditions and Requirements
This section details the critical conditions and requirements for applicants and funded projects, covering application stipulations, consortium formation, budget rules, and other specific provisions to ensure compliance and project success.
Application Procedure
This section guides applicants through the procedural aspects of the program, from how to submit proposals to the evaluation and selection processes. It highlights the structured steps involved in securing funding.
Legal Basis
This section outlines the fundamental legal and official documents that underpinned and governed the funding program, ensuring transparency and adherence to European regulations.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
15,000,000 €
Allocated Budget:
Up to 3 grants, each between 10,000,000 € and 15,000,000 €.
Deadline:
22.05.2024
Open Until:
Ongoing
Award Channel:
Framework Programme Call
Region:
European Union, Multi-Country (including EU Member States, Associated Countries, and specific non-EU/non-associated countries like Ukraine, Serbia, New Zealand)
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development, Information and Communication Technology, Software Development, Other
Beneficiaries:
Healthcare professionals, patients, healthcare systems, European health industries, researchers, regulators
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development, Commercialization, Implementation, Other
Funding Provider
Program Level:
European Union
Funding Body:
European Commission, Innovative Health Initiative Joint Undertaking (IHI JU)
Managed By:
Innovative Health Initiative Joint Undertaking (IHI JU)
Additional Partners:
Argentum Consultants.EU, Spindox Spa, RANIAROSE TECHNOLOGY LIMITED, GRANT GARANT SRO, Laboratory of Artificial Intelligence for Design, SYNYO, Tech2Market, ASSOCIATION FOR SUSTAINABLE INNOVATIVE DEVELOPMENTS IN ECONOMICS ENVIRONMENT AND SOCIETY, IMC- INDUSTRIAL MANAGEMENT CONSULTING SLOVAKIA, S.R.O., GOLEM - GESELLSCHAFT FUR INTEGRIERTE MIKROELEKTRONISCHE KOMPLETTLOESUNGEN GMBH, Dnipro state medical university, University of Belgrade - Faculty of Physical Chemistry, Scenic Biotech B.V., LC Innoconsult, Theta Biomarkers, PMO Yonetim ve Danismanlik A.S., Papanikolaou Hospital, FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA, EMPATICA SRL, FRUIT TREE LABS CREATIVE TECHNOLOGY, LDA, KGDiscovery, MMWR, YNIOS PHARMA SRL, DOKUZ EYLUL UNIVERSITESI, Iconovo AB, CHINO SRL, CEPHALGO, DIAGNOSTICUM GYARTO ES FORGALMAZO ZARTKORUEN MUKODO RESZVENYTARSASAG, Edinburgh Genetics Limited, AGENCIA PUBLICA EMPRESARIAL SANITARIA COSTA DEL SOL, LIONEX GMBH, Koios Care, HEMEX GERMANY GMBH, HEMEX Benelux BV, HEMEX AG, FUNDACION CENTRO TECNOLOXICO DE TELECOMUNICACIONS DE GALICIA, INTERSPREAD GMBH, MINDS & SPARKS GMBH, DEEP LAB IKE, PONS Teknoloji Ltd Sti, HIGOE Ltd, HOFITECH s.r.o., Novo Health, DISSEMINATION.COM, Stroke Rehab Ltd, Scinai Immunotherapeutics, MEDINNOVATE DYNAMICS, SSRD, VARNOST PROGRAMSKE OPREME, RAZISKAVE IN RAZVOJ, D.O.O., Science and Healthcare for Oral Welfare, M.D. BIOSCIENCES (ISRAEL) LTD, OSTEOARTHRITIS FOUNDATION INTERNATIONAL, Humanized Solutions, Lda, NUROMEDIA GMBH, CONCENTRIS RESEARCH MANAGEMENT GMBH, BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, VEIL.AI OY, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, NOTITIA DOO ZA SAVJETOVANJE I USLUGE, Azyro S.A., Metabio IKE, PREVING INVESTMENTS GROUP, S.L., OIKOPLUS GMBH, LLC BAZISMED, BUKOVINIAN STATE MEDICAL UNIVERSITY, BIOEMISSION TECHNOLOGY SOLUTIONS IKE, ZIEGLER AEROSPACE LIMITED, ASOCIATIA DE STANDARDIZARE DIN ROMANIA, HEALTH CITIZENS EUROPEAN INSTITUTE FOR HEALTH PROMOTION, CIIM INNOVATIONS LTD, C.I.P. CITIZENS IN POWER
Website: